Microsatellite instability cancer

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune, humanized) 1 substance
Unknown / small molecule 1 substance
Phase II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    MONALIZUMAB; VOLRUSTOMIG
    2024-511857-23-00 1 country n=43
    Ended

Phase I

2 trials
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502314-93-00 7 countries 2024 n=184
    Ended
  • Nykode Therapeutics ASA Commercial
    IMP not specified
    2023-509996-18-00 2 countries 2022 n=40
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 1 Phase I 0
Nykode Therapeutics ASA Commercial 1 Phase I 0
Assistance Publique Hopitaux De Paris Academic 1 Phase II 0
New trials by year
2022
1
2024
1
← All indication landscapes